EGFR and lung carcinoma: Wang et al.’s research in 2022 found that a significant number of NSCLC lung cancer patients in the high-incidence area of rural lung cancer in the coal-producing region of eastern Yunnan in southwest China carry the compound mutation of G719X + S768I, making up 16.67% of all EGFR mutations.